Notably, co-administration of the LSD1 inhibitor CC-90011 with DEX does not impair DEX anti-inflammatory effects, showing that LSD1 inhibition can selectively reduce GC-induced muscle atrophy without affecting their therapeutic benefits. This evidence concerns the gene KDM1A and muscle atrophy.